All patients in the FGFRa+ cohort and 54 patients in the FGFRa– cohort received anti–PD-(L)1 therapy (Fig. 1); two patients were excluded for not meeting the study eligibility criteria (one received an anti–PD-[L]1 agent prior to the date of advanced urothelial carcinoma diagnosis and a second did not receive an anti–PD-[L]1 agent). The gene discussed is CD274; the disease is urothelial carcinoma.